Etomerzol, a Soviet-era synthetic compound never approved as a medicine, was designed to help the body withstand heavy exertion, oxygen shortage and poisoning. Its developers' small early studies point toward faster poisoning recovery and better endurance under extreme strain, but no independent group has repeated them. The injectable form harmed injection sites, rats developed liver and kidney damage after about two weeks, and long-term safety for healthy adults is unknown. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 7–56 U/L | Liver injury seen in rats |
| AST | 10–40 U/L | Liver injury |
| Total bilirubin | 0.1–1.2 mg/dL | Liver processing function |
| Creatinine | 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women | Kidney-tubule damage |
| Platelet count | 150–450 ×10⁹/L | Platelet swings and bleeding risk |
| Blood pressure | No established target; track change from own baseline | Low blood pressure |
| Endurance benchmark (timed run or ride) | Improvement from own baseline | Defines success |
Cadence: Baseline before any exposure; laboratory tests at day 7 and at the end of a course, then 2–4 weeks after stopping if any value changed; blood pressure daily during the first 3 days